Periodontitis related marker and application thereof

Through ELISA detection and dynamic trend analysis of the glycochenodeoxycholic acid (GCDCA) marker in saliva, the invasiveness and lag problems of periodontitis diagnosis were solved, and non-invasive and accurate periodontitis activity assessment was achieved.

CN120779034APending Publication Date: 2025-10-14HOSPITAL OF STOMATOLOGY SUN YAT SEN UNIV
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202510972076.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-15
Publication Date
2025-10-14

AI Technical Summary

Technical Problem

Existing periodontitis diagnostic technologies are highly invasive, have a delayed nature, and lack specificity, making it impossible to achieve non-invasive, real-time assessment of periodontitis activity.

Method used

Glycochenodeoxycholic acid (GCDCA) was used as a salivary marker to assess periodontitis activity non-invasively. Anti-GCDCA monoclonal antibody and HRP-labeled GCDCA analog were used for ELISA detection. Dynamic trend analysis was performed using random forest model and support vector machine model.

Benefits of technology

It has achieved non-invasive, highly sensitive and highly specific periodontitis activity assessment, breaking through the lag limitations of traditional diagnosis and providing clinicians with a convenient, non-invasive and accurate diagnostic tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120779034A_ABST
    Figure CN120779034A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine, and particularly provides a periodontitis related marker which comprises glycochenodeoxycholic acid. The concentration change of the periodontitis related marker provided by the invention is directly related to the pathological mechanism of periodontitis. As bound bile acid, the bile acid is slowly degraded in saliva. And the glycochenodeoxycholic acid in the saliva is synthesized from gingival fibroblasts, so that the influence of systemic inflammatory diseases is greatly eliminated. Glycine chenodeoxycholic acid in saliva is used as a specific biomarker, a non-invasive, high-sensitivity and high-specificity detection method, system and equipment are established, objective quantitative evaluation and dynamic monitoring of periodontitis activity are achieved, the hysteresis limitation of traditional diagnosis is broken through, a convenient and non-invasive accurate diagnosis tool is provided for clinic, and the clinical application prospect is wide. And the technical blank of periodontitis activity noninvasive diagnosis is filled.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of biomedicine, and particularly relates to a periodontitis related marker and application. BACKGROUND

[0002] Periodontitis is a chronic inflammatory disease caused by dental plaque biofilm, which can lead to periodontal tissue destruction and tooth loss. Activity assessment of periodontitis is crucial for guiding precise treatment, predicting disease progression and monitoring efficacy.

[0003] The existing periodontitis activity judgment mainly includes clinical examination, microbial detection, gingival crevicular fluid analysis and saliva analysis. Among them, the probing of clinical examination may cause pain or error of the patient, the result depends on the experience of the doctor, lacks objective quantitative indicators, and can only reflect the occurred tissue destruction (such as alveolar bone absorption), cannot monitor the inflammatory activity in real time, and leads to delayed treatment opportunity; the microbial detection mainly detects pathogenic bacteria in subgingival plaque through culture or molecular biology technology, the plaque sampling technology has high requirements, long time consumption and high cost, and the clinical application is limited; the gingival crevicular fluid analysis needs to detect inflammatory factors such as prostaglandin (PGE2) and matrix metalloproteinase, although the sensitivity is high, the operation is complex, and the small amount of gingival crevicular fluid sampling will affect the stability; the saliva analysis needs to detect saliva inflammatory factors interleukin (IL-6, IL-8) or enzymes (such as MMP-8), these inflammatory factors will also increase in other diseases such as caries and diabetes, which is easy to lead to misdiagnosis. SUMMARY

[0004] The purpose of the present application is to overcome the limitations of the existing periodontitis diagnosis technology, such as invasiveness, hysteresis and insufficient specificity.

[0005] To this end, the present application provides a periodontitis related marker, which comprises glycochenocholic acid.

[0006] The present application also provides a kit for periodontitis activity diagnosis, efficacy monitoring or recurrence prediction, comprising an anti-glycochenocholic acid monoclonal antibody coated plate.

[0007] Specifically, the above-mentioned kit further comprises horseradish peroxidase labeled GCDCA analog.

[0008] The present application also provides a non-invasive periodontitis activity evaluation method, comprising the following steps:

[0009] S1, collecting saliva samples of the subject and pretreating;

[0010] S2, detecting the concentration of glycochenocholic acid in the saliva sample;

[0011] S3, evaluating the activity of periodontitis based on the threshold value or dynamic change trend of glycochenocholic acid concentration.

[0012] Specifically, the pretreatment in step S1 includes: after the saliva sample is centrifuged to remove impurities, the saliva sample is concentrated using an ultrafiltration tube with a molecular weight cut-off of 3 kDa.

[0013] Specifically, the glycochenodeoxycholic acid concentration threshold is set at 4.5 ng / mL.

[0014] The present invention also provides a periodontitis activity assessment system, comprising:

[0015] An input module, used for inputting sample parameters; the sample parameters include the concentration of glycochenodeoxycholic acid in saliva;

[0016] An evaluation module is used to perform periodontitis activity analysis based on a dynamic trend model with the glycochenodeoxycholic acid concentration as a variable to obtain a periodontitis activity score result.

[0017] The present invention also provides a periodontitis activity assessment device, comprising the above system and further comprising:

[0018] A detection device for detecting the concentration of glycochenodeoxycholic acid in a saliva sample;

[0019] The output device is used to output the periodontitis activity score result.

[0020] Specifically, the above-mentioned periodontitis activity assessment device also includes a saliva collector.

[0021] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0022] The periodontitis-related markers provided by the present invention include glycochenodeoxycholic acid, which can participate in the progression of periodontitis by regulating oral flora, gingival epithelial barrier and host immune response (such as macrophage polarization), and its concentration change is directly related to the pathological mechanism of periodontitis. As a conjugated bile acid, it degrades slowly in saliva. Moreover, GCDCA in saliva is synthesized by gingival fibroblasts, which greatly eliminates the influence of systemic inflammatory diseases. Using glycochenodeoxycholic acid (GCDCA) in saliva as a specific biomarker, a non-invasive, highly sensitive and highly specific detection method, system and equipment are established to achieve objective quantitative evaluation and dynamic monitoring of periodontitis activity, breaking through the hysteresis limitations of traditional diagnosis, providing a convenient, non-invasive and accurate diagnostic tool for clinicians, and filling the technical gap of non-invasive diagnosis of periodontitis activity.

[0023] The present invention will be described in further detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1These are the results of Spearman correlation analysis between the concentrations of various bile acids in the oral cavity and clinical indicators of periodontitis.

[0025] Figure 2 These are the results of Spearman correlation analysis between the proportion of conjugated bile acids in the oral cavity and clinical indicators of periodontitis.

[0026] Figure 3 is the result of the rank sum test of the ratio of conjugated bile acids to unconjugated bile acids.

[0027] Figure 4 It is the feature of random forest tree algorithm to analyze the concentration of various bile acids in the oral cavity.

[0028] Figure 5 ELISA was used to detect the concentration of GCDCA in gingival tissue and peripheral blood.

[0029] Figure 6 are the test results of gingival epithelial barrier and alveolar bone; among them, A is the result of gingival epithelial barrier permeability detection by FITC-Dextran fluorescence method; B is the result of Western blot analysis of gingival epithelial cell barrier protein; C is the micro-CT scan image of maxillary alveolar bone tissue; D is the calculation of the percentage of bone volume fraction to the total volume of the standard space by creating a standard space in the micro-CT image; E is the calculation of maxillary alveolar bone volume loss based on bone volume fraction (BVF = bone volume ÷ total volume of the standard space, n = 4); F is the expression of S1PR2 in mouse gingival tissue detected by qPCR.

[0030] Figure 7 The results are the expression results of CYP27A1 and CYP7B1 in gingival fibroblasts in periodontitis state.

[0031] Figure 8 This is a heat map showing the expression changes of CYP27A1 and CYP7B1 in gingival fibroblasts after LPS stimulation.

[0032] Figure 9 The results of Western blot detection of CYP27A1 and CYP7B1 expression in gingival fibroblasts after LPS stimulation.

[0033] Figure 10 The ELISA method was used to detect the GCDCA synthesis level of gingival fibroblasts under LPS stimulation.

[0034] Figure 11 The receiver operating characteristic (ROC) curve was used to evaluate the classification and discrimination ability of the metabolic marker GCDCA. DETAILED DESCRIPTION

[0035] The technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Although the representative embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes can be made to the present invention without departing from the scope of the present invention. Therefore, the scope of the present invention should not be limited to the embodiments, but should be defined by the appended claims and their equivalents.

[0036] The present invention provides a periodontitis-related marker, which includes glycochenodeoxycholic acid (GCDCA) in saliva.

[0037] The present invention also provides a kit for diagnosing periodontitis activity, monitoring therapeutic efficacy, or predicting relapse, comprising an anti-glycochenodeoxycholic acid monoclonal antibody-coated plate (e.g., a 96-well plate pre-coated with an anti-GCDCA monoclonal antibody) and a GCDCA analog labeled with horseradish peroxidase (HRP). The GCDCA analog is a class of molecules that have been chemically modified to impart labeling or detection capabilities without altering their antigenic determinant recognition capabilities. These include, but are not limited to: GCDCA-6α-amino: an amino group is introduced at the 6α position of the bile acid ring, which can be used for coupling to a fluorophore or enzyme; GCDCA-NHSester: the carboxyl group is activated to an NHS ester form, facilitating coupling to enzymes or carrier proteins (e.g., HRP, BSA); GCDCA-biotin: linked to biotin, which can be used for detection in an avidin system; and HRP conjugates with similar GCDCA structures. The HRP-labeled GCDCA analog retains the antigenicity of GCDCA in its core structure and has the ability to compete with specific antibodies for binding. This kit is a competitive ELISA kit that optimizes detection efficiency and cost, and the detection time can be shortened to 20 minutes.

[0038] The present invention also provides a non-invasive method for assessing periodontitis activity, comprising the following steps:

[0039] S1. Collect saliva samples from subjects and perform pretreatment.

[0040] (1) Saliva collection: Use a standardized saliva collection tube (preferably containing 1 mL of sample preservation solution, components: 0.1% sodium azide preservative, 5 mM EDTA anticoagulant, 0.5% protease inhibitor) to collect the subject's non-stimulated saliva that does not contain sputum, food residues, and blood.

[0041] (2) Storage and transportation: Refrigerate the sample immediately after collection (preferably at 4°C) and complete the test within 24 hours. If long-term storage is required, freeze it at -80°C (degradation rate <5% / month).

[0042] (3) Pretreatment: Centrifugation to remove exfoliated epithelial cells and food residues, and ultrafiltration to concentrate saliva samples.

[0043] S2. Detect the concentration of glycochenodeoxycholic acid in saliva samples.

[0044] The concentration of GCDCA in saliva was quantified by enzyme-linked immunosorbent assay (ELISA) as follows:

[0045] (1) Kit composition: 96-well plate pre-coated with anti-GCDCA monoclonal antibody, horseradish peroxidase (HRP)-labeled GCDCA analog.

[0046] (2) Add diluted samples (containing target GCDCA) and HRP-labeled GCDCA analogs to the pre-coated wells to form a competitive system.

[0047] (3) Incubate until antigen-antibody binding reaches equilibrium.

[0048] (4) Wash to remove unbound free HRP label.

[0049] (5) Add 3,3',5,5'-tetramethylbenzidine (TMB) substrate to each well and incubate in the dark for color development. HRP catalyzes TMB to generate a blue product.

[0050] The reaction was terminated by adding the stop solution, and the solution turned yellow. The color depth was inversely proportional to the amount of bound HRP (i.e., positively correlated with the GCDCA concentration of the sample).

[0051] (6) Absorbance determination: The absorbance value (OD value) was read at 450 nm (main wavelength) and 630 nm (reference wavelength) using a microplate reader.

[0052] Construct a standard concentration curve and infer the GCDCA concentration based on the sample OD value.

[0053] S3. Evaluate periodontitis activity based on the glycochenodeoxycholic acid concentration threshold or dynamic change trend.

[0054] Specifically, the glycochenodeoxycholic acid concentration threshold is set at 4.5 ng / mL, and if the concentration exceeds this threshold, it is determined to be in the active stage.

[0055] The present invention also provides a periodontitis activity assessment system, comprising:

[0056] An input module for inputting sample parameters; the sample parameters include the concentration of glycochenodeoxycholic acid in saliva; to improve the accuracy and sensitivity of the assessment, the sample parameters may also include the rate of change of glycochenodeoxycholic acid concentration over time (ΔGCDCA / Δt), clinical parameters (probing depth, bleeding index), and baseline characteristics (age, smoking history, diabetes status);

[0057] The evaluation module is used to perform periodontitis activity analysis based on a dynamic trend model (random forest model, SVM model) with the glycochenodeoxycholic acid concentration as a variable to obtain a periodontitis activity score result. In later applications, the disease progression and recurrence risk can be predicted based on the score result.

[0058] The present invention also provides a periodontitis activity assessment device, comprising the above system and further comprising:

[0059] Saliva collectors: These can be integrated with a built-in sample stabilization reagent (lyophilized powder) that automatically mixes with the preservation solution after sampling. They can also be equipped with a Bluetooth connection module to record metadata such as sampling time and temperature in real time.

[0060] The detection device is used to detect the concentration of glycochenodeoxycholic acid in a sample; it uses an automated analyzer and can be set as a desktop device, integrating an ELISA detection unit (with a replaceable reagent cartridge) and a microfluidic chip.

[0061] The output device is used to output the periodontitis activity score result.

[0062] Specifically, the evaluation module and the output device can be integrated into a data analysis platform; the data analysis platform is used to automatically match the threshold model after receiving the detection data input by the input module, generate a visual report (including concentration values, trend charts, and risk levels), and support multimodal data fusion (such as combining CBCT image bone density data).

[0063] Furthermore, the device also includes a cloud database for storing patient historical data, and can continuously optimize the diagnostic model through machine learning (such as updating thresholds or weight parameters).

[0064] Furthermore, it also includes a doctor-side APP and a patient-side mini-program to provide remote diagnosis and treatment recommendations and follow-up reminders.

[0065] The periodontitis activity assessment device provided by this invention collects saliva non-invasively, causing no discomfort to the patient, and can be operated by non-periodontists, facilitating large-scale screening, public welfare clinics, and home testing. Based on a portable testing system (such as an ELISA rapid analyzer), it supports continuous sampling and trend analysis, overcoming the hysteresis limitations of traditional methods. Furthermore, interpretation of the results does not require a periodontist.

[0066] The periodontitis-related markers of the present invention and the effects of their application are studied below through specific examples.

[0067] Example 1:

[0068] This example included 31 samples from subjects, 18 of which were from periodontitis patients and 13 from healthy subjects. The bile acid targeted metabolomics technology was used to analyze the saliva of periodontitis patients and healthy subjects. Figures 1-5 shown.

[0069] In this experiment, targeted metabolomics detected a total of 29 bile acids and their derivatives. Compared with healthy people, the oral bile acid pool of periodontitis patients was disordered, specifically manifested as: increased total bile acid concentration, increased proportion of conjugated bile acids, and decreased proportion of unconjugated bile acids. In addition, the proportion of conjugated bile acids was also significantly positively correlated with periodontitis indicators such as attachment loss, probing depth, and percentage of bone loss, suggesting that the pro-inflammatory effect of conjugated bile acids is dominant in the bile acid pool ( Figures 1-4 ).

[0070] The random forest tree algorithm was then used to screen the bile acids that have the greatest impact on periodontitis. The results showed that glycochenodeoxycholic acid (GCDCA) is a key biomarker for periodontitis ( Figure 5 GCDCA, a conjugated bile acid synthesized by the human body, not only showed significantly elevated concentrations in the periodontitis group but was also highly correlated with the severity of periodontitis. GCDCA is an important signaling molecule that binds to various cell surface receptors, influencing the physiological processes of various diseases. It is a major activator of the sphingosine 1-phosphate receptor 2 (S1PR2). It can activate S1PR2 to disrupt the epithelial barrier and regulate the M1 / M2 polarization of macrophages, thereby exacerbating the damage caused by periodontitis.

[0071] The concentration of GCDCA in the gingival tissue and peripheral blood of periodontitis patients and healthy people was detected. It was found that although there was no difference in the GCDCA concentration in the peripheral blood of the two groups, the concentration of GCDCA in the gingival tissue of periodontitis patients was significantly increased ( Figure 5 ), indicating that the changes in GCDCA concentration in saliva are consistent with those in gingival tissue, indicating that the activity of periodontitis can be predicted by a non-invasive and simple salivary GCDCA detection method.

[0072] Example 2:

[0073] GCDCA (0.1 mM) and S1PR2 inhibitor JTE013 (0.1 mM) were co-cultured with cultured gingival epithelial cells for 12 h, and the FITC-Dextran permeation assay was used to detect the permeation of FITC-Dextran molecules across the epithelial layer after co-culture.

[0074] The cells were collected and the protein levels of gingival epithelial barrier function-related proteins E-cadherin and Claudin-1 and epithelial extrusion-related molecule S1PR2 were detected by Western blot.

[0075] Eight-week-old C57 / BJ6 mice were divided into four groups: control, periodontitis group (Ligature), GCDCA + periodontitis co-culture group (Ligature + GCDCA), and JTE-013 + GCDCA + periodontitis group (Ligature + GCDCA + JTE013), with six mice in each group. The periodontitis model group underwent bilateral ligature ligation at the cervical region of the maxillary and mandibular second molars using 5-0 silk suture. On the first and fourth days after ligation, 10 μL of LPS-PG (5 μg / μL) was injected into the buccal gingival sulcus at the ligature site. Equal volumes of 4% CMC gel were added to the GCDCA and JTE-013 solutions. The GCDCA + periodontitis and JTE-013 + GCDCA + periodontitis groups were treated with 0.5 mg / day of CMC gel every other day. Mice in the control group were treated with 2% CMC gel every other day. The model was established for four weeks. Maxillary alveolar bone tissue was scanned by micro-CT. A standard space was created in the micro-CT images, and the percentage of bone volume fraction to the total volume of the standard space was calculated. Bone loss was calculated as bone volume fraction (BVF = bone volume ÷ total volume of the standard space, n = 4). qPCR was used to detect the expression of S1PR2 in mouse gingival tissue.

[0076] The results are as follows Figure 6 As shown. In vitro, GCDCA increased the permeability of the gingival epithelial barrier and reduced the expression of barrier-related proteins (Claudin-1 and E-cadherin), thereby impairing epithelial barrier function. The S1PR2 inhibitor JTE013 mitigated these damaging effects. In vivo, GCDCA significantly promoted ligature-induced alveolar bone resorption in mice and upregulated S1PR2 expression. Treatment with JTE013 attenuated GCDCA-induced alveolar bone resorption.

[0077] Example 3:

[0078] Integration of single-cell RNA sequencing data from periodontal tissues revealed that the alternative bile acid synthesis pathway was significantly enriched in gingival fibroblasts, and that CYP27A1 and CYP7B1, genes encoding bile acid synthases involved in the alternative pathway, were highly expressed only in gingival fibroblasts under periodontitis conditions. Figure 7 After integrating the in vitro transcriptome data of gingival fibroblasts, it was found that they can express all metabolic enzyme genes required for GCDCA synthesis, and there is a general trend of upregulation of expression under LPS stimulation ( Figure 8 Gingival epithelial cells were cultured in vitro and stimulated with different concentrations of 0.5 μg / mL lipopolysaccharide from Porphyromonas gingivalis (LPS-PG, InvivoGen) for 24 h. Fibroblasts from each group were collected and the protein levels of CYP27A1 and CYP7B1 were detected by Western Blot. Figure 9 ); The culture supernatant of fibroblasts from each group was collected, and the samples were pretreated and the GCDCA concentration was detected according to the instructions of the GCDCA ELISA kit (MEIMIAN). Figure 10 Western blot results showed that the expression levels of CYP27A1 and CYP7B1 were significantly increased in gingival fibroblasts after LPS stimulation. ELISA assays verified the GCDCA synthesis and exocytosis capacity of gingival fibroblasts under LPS stimulation and found that GCDCA synthesis was significantly increased under LPS stimulation, while GCDCA synthesis was significantly reduced in CYP7B1 low-expressing strains. These studies suggest that the increased GCDCA in periodontal inflammation may be derived from the enhancement of the alternative bile acid synthesis pathway in gingival fibroblasts. They also demonstrate that the elevated GCDCA in the saliva of periodontitis patients is oral-specific and less affected by systemic inflammation.

[0079] Example 4:

[0080] This embodiment provides a non-invasive method for assessing periodontitis activity, comprising the following steps:

[0081] S1. Collect saliva samples from subjects and perform pretreatment.

[0082] (1) Collection method

[0083] Subject preparation: Subjects need to wake up in the morning on an empty stomach (no food or water for more than 2 hours), avoid brushing teeth or using mouthwash to reduce exogenous interference.

[0084] Saliva collection: Using a standardized saliva collection tube (containing 1 mL of sample preservation solution, consisting of 0.1% sodium azide preservative, 5 mM EDTA anticoagulant, and 0.5% protease inhibitor), 3 mL of non-stimulated saliva, free of sputum, food residue, and blood, was collected from each participant.

[0085] Storage and transportation: The sample should be stored at 4℃ immediately after collection and the test should be completed within 24 hours. If long-term storage is required, the sample should be stored at -80℃ (degradation rate <5% / month).

[0086] (2) Pretreatment

[0087] Centrifugation to remove impurities: centrifuge at 3000 rpm for 10 minutes to remove exfoliated epithelial cells and food residues.

[0088] Ultrafiltration and concentration: use an ultrafiltration tube with a molecular weight cutoff of 3 kDa to concentrate the saliva sample (10-fold enrichment of GCDCA)

[0089] (2) GCDCA concentration detection technology: ELISA rapid detection method (clinical grade):

[0090] S2, detect the concentration of glycochenodeoxycholic acid in saliva samples.

[0091] (1) Kit composition

[0092] Pre-coated 96-well plate with anti-GCDCA monoclonal antibody, horseradish peroxidase (HRP) labeled GCDCA analog, which is GCDCA-6α-amino.

[0093] (2) Sample addition and competition reaction

[0094] Add 50 μL of diluted sample (containing target GCDCA) to the pre-coated well, and add 50 μL of HRP labeled GCDCA analog to form a competition system and compete for antibody binding.

[0095] Incubate at 37℃ for 30 minutes to promote antigen-antibody binding to equilibrium.

[0096] Use an automatic plate washer or manually wash the plate, inject 300 μL of washing buffer into each well, stand for 30 seconds, then discard the liquid, repeat 5 times. Remove non-bound free HRP labeled material to reduce background signal.

[0097] (3) Color development and detection

[0098] Add 100 μL of 3,3',5,5'-tetramethylbenzidine (TMB) substrate to each well, incubate in the dark for 10 minutes, and HRP catalyzes the generation of blue product from TMB.

[0099] Add 50 μL of stop solution, the solution turns yellow, and the color depth is inversely proportional to the amount of bound HRP (i.e. positively correlated with the GCDCA concentration of the sample).

[0100] Use a microplate reader to read the absorbance value (OD value) at 450 nm (primary wavelength) and 630 nm (reference wavelength).

[0101] (4) Data Analysis

[0102] Standard curve fitting: With the concentration of the standard as the horizontal axis and the corresponding OD value as the vertical axis, fit a 4-parameter logistic curve (or linear regression).

[0103] Concentration calculation: The GCDCA concentration is calculated based on the sample OD value and a report is automatically generated.

[0104] S3. Evaluate periodontitis activity based on the glycochenodeoxycholic acid concentration threshold or dynamic change trend.

[0105] (1) Based on the detection of GCDCA in the saliva of periodontitis and non-periodontitis patients by targeted metabolomics in Example 1, the classification and discrimination ability of the metabolite marker GCDCA was further evaluated by the receiver operating characteristic (ROC) curve. Analysis results ( Figure 11 ) showed that its area under the curve (AUC) reached 0.863, indicating that GCDCA concentration has high discriminatory power in identifying active periodontitis. Based on the maximum Youden index principle, the optimal clinical diagnostic threshold was determined to be 4.5 ng / mL, achieving a sensitivity of 94% and a specificity of 69% at this point. This indicator can serve as a decision support variable for identifying inflammatory states and improve the clinical adaptability of the overall model. The glycochenodeoxycholic acid concentration threshold was set at 4.5 ng / mL; concentrations above this threshold are considered active.

[0106] (2) The GCDCA concentration in the saliva of the subjects was detected at different time points, the rate of change of GCDCA concentration (ΔGCDCA / Δt) was calculated, and the trend of periodontitis activity was evaluated in combination with the threshold.

[0107] Example 5:

[0108] The present invention also provides a periodontitis activity assessment device, including a saliva collector, a detection device, an input module, an assessment module, and an output device. The details of each module device are as follows.

[0109] Saliva collector, integrated design, built-in sample stabilization reagent (lyophilized powder form), automatically mixes the preservation solution after sampling;

[0110] Detection device, integrating ELISA detection unit (replaceable reagent cartridge) and microfluidic chip;

[0111] An input module for inputting sample parameters, including salivary GCDCA concentration, sampling time, rate of change of GCDCA concentration over time (ΔGCDCA / Δt), clinical parameters (probing depth, bleeding index), and baseline characteristics (age, smoking history, and diabetes status);

[0112] The evaluation module, comprising a threshold decision model and a dynamic trend analysis model, automatically fits the model to the test data input from the input module. The threshold decision model sets the GCDCA concentration threshold at 4.5 ng / mL. The dynamic trend analysis model uses a random forest model combined with an elastic network regression algorithm (Elastic Net) to construct a scoring function. The input features are probing depth (PD), bleeding opacity (BOP), number of lost teeth (TL), GCDCA concentration status (whether it exceeds 4.5 ng / mL), and its actual concentration (GCDCA_ng / mL). The output target variable is a clinically assessed comprehensive inflammation score. The dataset was processed for missing values ​​and normalized before modeling. The dataset was then split into a training set and a validation set in an 80%:20% ratio for model construction and performance evaluation. The model uses the Elastic Net regression algorithm with a regularization coefficient of α = 0.5. This model combines L1 regularization (for feature selection) and L2 regularization (for stability), making it particularly suitable for modeling medical data with small sample sizes and strong multi-feature collinearity. The optimal regularization parameter λ = 0.0372 was determined by 5-fold cross validation, and good fitting performance (RMSE = 0.590, R 2 =0.950), indicating that the model has good generalization ability and stability. The constructed regression scoring function is as follows:

[0113] Risk Socre=-0.168+0.017×PD+5.848×BOP+0.030×TL+0.725×gCDCA status +0.018×gCDCA ng / mL

[0114] Among them, GCDCA_status is a binary variable (0 means ≤4.5ng / mL, 1 means >4.5ng / mL). In order to enhance the clinical adaptability of the scoring system, the present invention comprehensively quotes the 2018 AAP / EFP new periodontitis classification standard and adopts the "Stage + Grade integration system" to construct an inflammation scoring label. Stage I-IV is encoded as 1-4 points, Grade AC is encoded as 1-3 points, and the total score range of the two is 2-7. Literature and expert consensus show that: Stage III+Grade B or Stage II+Grade C (total score = 5) is medium risk, and Stage III+Grade C or above (total score ≥6) is high risk. Therefore, if the output value predicted by this model corresponds to a total score >5, it indicates a high-risk inflammatory state, and it is necessary to initiate systematic treatment intervention and increase the frequency of follow-up visits.

[0115] The output device is used to output the periodontitis activity score results and generate a visual report (including concentration values, trend graphs, and risk levels).

[0116] The above examples are merely illustrative of the present invention and do not limit the scope of protection of the present invention. Any design that is identical or similar to the present invention falls within the scope of protection of the present invention.

Claims

1. A periodontitis-related marker, characterized by: Such markers include glycochenodeoxycholic acid.

2. Use of the marker according to claim 1 in the preparation of products for diagnosing periodontitis activity, monitoring therapeutic efficacy or predicting recurrence.

3. A kit for diagnosing periodontitis activity, monitoring therapeutic efficacy, or predicting relapse, characterized by: Includes anti-glycochenodeoxycholic acid monoclonal antibody coated plates.

4. The kit according to claim 3, wherein: Also included are horseradish peroxidase-labeled GCDCA analogs.

5. A non-invasive method for assessing periodontitis activity, characterized in that: The following steps are involved: S1. Collect saliva samples from subjects and perform pretreatment; S2, detecting the concentration of glycochenodeoxycholic acid in saliva samples; S3. Evaluate periodontitis activity based on the glycochenodeoxycholic acid concentration threshold or dynamic change trend.

6. The non-invasive periodontitis activity assessment method according to claim 5, wherein: The pretreatment in step S1 includes: centrifuging the saliva sample to remove impurities, and then ultrafiltration to concentrate the saliva sample.

7. The non-invasive periodontitis activity assessment method according to claim 5, wherein: The glycochenodeoxycholic acid concentration threshold was set at 4.5 ng / mL.

8. A periodontitis activity assessment system, characterized in that: include: An input module, used for inputting sample parameters; the sample parameters include the concentration of glycochenodeoxycholic acid in saliva; An evaluation module is used to perform periodontitis activity analysis based on a dynamic trend model with the glycochenodeoxycholic acid concentration as a variable to obtain a periodontitis activity score result.

9. A periodontitis activity assessment device, characterized in that: The system according to claim 8, further comprising: A detection device for detecting the concentration of glycochenodeoxycholic acid in a saliva sample; The output device is used to output the periodontitis activity score result.

10. The apparatus for diagnosing periodontitis according to claim 1, wherein: A saliva collector is also included.

Citation Information

Patent Citations

  • Methods of decreasing dysbiosis and restoring a microbiome

    CN112888447A

  • Rheumatoid arthritis blood diagnosis kit and application thereof

    CN114062532A

  • Modulation of microbiome function by gene therapy of microbiome to prevent, treat or cure microbiome related diseases or disorders

    CN115427565A

  • Combination therapy for the treatment of immunoinflammatory disorders

    CN1761478A

  • Ceiling lamp with an earthquake-proof bracket

    KR102479209B1